CholedochojeJunostomy stricture
Conditions
Interventions
For cholangiojejunostomy stenosis, the test treatment group will be treated with balloon dilation alone, and the control treatment group will be treated with a combination of balloon dilation and sten
Sponsors
Shimane University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Have a history of treatment for bile duct jejunostomy. 2) Elevated hepatobiliary enzymes within 90 days before enrollment. The above was approved. 3) Intrahepatic bile duct dilatation is found on imaging tests. 4) No serious renal disorder (latest serum creatinine value less than 2.0 mg/dl and eGFR 30 ml/min/1.73 m2 or more within 28 days before registration). 5) Do not have severe diabetes (no concurrent diabetes or latest HbA1c less than 10% within 28 days before registration). 6) Be at least 18 years old at the time of consent. 7) Written consent has been obtained from the individual to participate in the research.
Exclusion criteria
Exclusion criteria: 1) Have a history of hypersensitivity to iodine or iodine contrast media. 2) Have poorly controlled hyperthyroidism (thyroid function is not stable despite untreated status or treatment). 3) Have a serious heart disorder (acute myocardial infarction, intractable arrhythmia, or other severe heart disease) 4) Have serious lung disease (with symptoms such as hypoxemia and difficulty breathing). 5) Have active multiple cancers (synchronous multiple cancers and metachronous multiple cancers with a disease-free period of 5 years or less). However, this does not include carcinoma in situ, which is considered to be curable with treatment. 6) Concomitant disseminated intravascular coagulation (meeting the diagnostic criteria of the Japanese Society of Thrombosis and Haemostasis DIC diagnostic criteria 2017 edition [12]). 7) Having biliary stricture due to malignant tumor. 8) I am pregnant. 9) A bile duct jejunostomy other than an anastomosis is confirmed by imaging test (ultrasound, CT, or MRI) or ERCP.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cholangitis recurrence-free survival | — |
Countries
Japan
Contacts
Public ContactNOBUHIKO FUKUBA
Shimane University Internal medicine II
Outcome results
None listed